BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05064735 (Semaglutide in Knee Osteoarthritis): BVCT ex-ante prediction vs. reported outcome

On 9 Oct 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 23 Apr 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05064735
Acronym
STEP 9
Drug Name
Semaglutide
Drug MoA
GLP1R agonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Knee Osteoarthritis
Human Patients
407
Sponsor
Novo Nordisk
Phase
Phase 3

Prediction of , index 1272

Prospective Prediction
Prediction Index
1272
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
197 days in advance
Readout Data Interpretation
semaglutide achieved a placebo-adjusted -14.2 WOMAC pain reduction (P<0.001)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis
Phase
Phase 3
Status
Completed
Enrollment
407
Lead sponsor
Novo Nordisk A/S
Conditions
Obesity
Interventions
DRUG: semaglutide 2.4 mg; DRUG: semaglutide 2.4 mg (placebo)
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2021-10-01
Primary completion
2023-07-24
Completion
2023-09-08
Results first posted
2024-08-13
Primary outcomes
  • Percentage Change in Body Weight (Baseline (week 0), end of treatment (week 68))
  • Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score (Baseline (week 0), end of treatment (week 68))

NCT05064735 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials